Immunotherapy Dosing for Solid Tumors
This study is looking at how different doses of standard immunotherapy drugs, Nivolumab and Pembrolizumab, affect side effects in people with solid tumors. Researchers want to see if higher doses (Nivolumab 480mg every 4 weeks or Pembrolizumab 400mg every 6 weeks) lead to more severe immune-related side effects (irAEs) compared to lower doses (Nivolumab 240mg every 2 weeks or Pembrolizumab 200mg every 3 weeks). You might be able to join if you are 18 or older, have a solid tumor, and meet other health requirements. The study will measure these side effects over 12 weeks. The goal is to understand how to best use these important cancer treatments.
- Study design
- This is an open-label, randomized study with two groups, and it plans to enroll 192 participants. It is a Phase 3/4 study.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary side effects will be measured at 12 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
At a glance
Conditions
NCT07174453
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
The University of Kansas Cancer Center
Westwood, Kansasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Anup Kasi, MD · PRINCIPAL_INVESTIGATOR · University of Kansas Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportions of grade ≥3 immune related adverse events (irAEs) between the two arms in each cohort12 weeks
Measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 5.0